Breaking News Instant updates and real-time market news.

AGN

Allergan

$146.77

-1.53 (-1.03%)

08:32
12/19/18
12/19
08:32
12/19/18
08:32

Allergan suspends sales of textured breast implants in European markets

Allergan announced that the company has suspended sales of textured breast implants and tissue expanders and is withdrawing any remaining supply in European markets. The withdrawal decision follows a compulsory recall request from Agence Nationale de Securite du Medicament, the French regulatory authority. The suspension of sales stems from the expiration of the company's CE Mark for these products. Although Allergan disagrees with ANSM's request, the Company is fully cooperating with the authority. Allergan stands behind the benefit/risk profile of our breast implant products. The ANSM request, and this action, is not based on any new scientific evidence regarding these products. Furthermore, ANSM has not identified any immediate risk to the health of women with textured breast implants. The Company looks forward to participating in the scientific forum that ANSM has scheduled for early February where the full set of data and scientific evidence for textured breast implants can be presented and thoroughly discussed by all stakeholders. Allergan will continue to work through the CE Mark renewal with GMED, and is planning an appeal to ensure that appropriate patients have access to the products that their surgeons recommend. Importantly, the CE Mark for Allergan's smooth implants has been renewed by GMED. Smooth implants are not affected and continue to be available for patients. It is also important to note that the United States does not require the CE Mark so it is unaffected by the action.

  • 05

    Jan

AGN Allergan
$146.77

-1.53 (-1.03%)

12/17/18
PIPR
12/17/18
NO CHANGE
Target $164
PIPR
Overweight
Shire approval another potential headwind for Allergan, says Piper Jaffray
Piper Jaffray analyst David Amsellem views Shire's (SHPG) FDA approval Friday for its 5-HT4 receptor agonist Motegrity in chronic idiopathic constipation as another potential headwind for Allergan's (AGN) Linzess. The headwind is not necessarily in terms of pressure on volumes, but more in terms of the potential for a more challenging payer environment, Amsellem tells investors in a research note. The analyst remains cautious on Allergan given his concerns regarding the trajectory of the commercial portfolio as well as its pipeline. Amsellem reiterates a Neutral rating on the stock with a $164 price target.
12/12/18
STFL
12/12/18
NO CHANGE
Target $35
STFL
Buy
Synergy's GI assets 'fit squarely' into Bausch Health GI wheelhouse, says Stifel
Stifel analyst Annabel Samimy notes that Bausch Health (BHC) entered into a "stalking horse" bid to acquire through bankruptcy proceedings substantially all of Synergy Pharmaceutical's (SGYP) GI assets, which includes rights to Trulance/plecanotide, dolcanatide and its intellectual property. While still subject to competitive bids, these assets "fit squarely" into Bausch Health's GI wheelhouse, which would immediately leverage the company's sales and payer infrastructure and physician relationships in the space, the analyst contends. Though competitive with Allergan's (AGN) Linzess, Bausch Health has proven a strong player in the GI space and she thinks it is exactly the presence needed to optimize/maximize sales of Trulance, with its strong efficacy and tolerability profile. Samimy reiterates a Buy rating and $35 price target on Bausch Health's shares.
12/03/18
PIPR
12/03/18
NO CHANGE
Target $65
PIPR
Overweight
Piper says buy Biohaven 'aggressively' after 'impressive' data
Biohaven Pharmaceutical (BHVN) this morning reported "impressive" topline data from the Phase III trial testing the Zydis orally dissolving tablet formulation of rimegepant, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The study not only achieved statistical significance on both co-primary endpoints, "but surprisingly" also demonstrated an "incredibly rapid" 15 minute onset of action, says the analyst. Further, he notes that Biohaven reported pooled safety data from what is now three Phase III rimegepant studies and that the candidate "continues to be safe and well tolerated" with no signal of liver toxicity. Van Buren believes the new data "definitely makes" rimegepant a superior product to Allergan's (AGN) ubrogepant and the "best-in-class" oral calcitonin gene-related peptide. He reiterates an Overweight rating on Biohaven with a $65 price target and recommends that investors buy the stock "aggressively."
11/30/18
RBCM
11/30/18
NO CHANGE
Target $220
RBCM
Outperform
RBC shares investor frustration, but sees 'unlocked value' in Allergan
In a research note last night titled "Is it time for bold change at AGN? Investor frustration is high but value remains," RBC Capital analyst Randall Stanicky said he continues to see "significant unlocked value" in shares of Allergan. The analyst added that like many investors, he's frustrated. While it's easy to point to pipeline opportunity, after three years of underperformance, debate around whether it is time for bigger change has justifiably returned, Stanicky wrote. The reality, according to the analyst, is that both Allergan's pipeline and the potential push for a break-up "add optionality" on an "already compelling valuation." Amidst this backdrop, the analyst believes the focus on next week's conference update will be high. While there has been some positive evolution, like the board refresh and reduced focus on big acquisitions, the company's overall strategy is "unchanged and premised on investor appetite to own a platform comprised of various therapeutic assets combined via historical specialty pharma consolidation," says Stanicky. He believes investor frustration "is justified as is a sense of urgency to address performance." Nonetheless, the analyst's view on Allergan remains unchanged. He sees "attractive pipeline opportunity" with the greater value creation opportunity coming from a "more aggressive platform revisit/break-up." Both the potential for a strategic revisit and pipeline add to the stock's attractive risk/reward, contends Stanicky. Divesting Women's Health and/or Anti-infectives may seem incremental, but it would still be a "positive first step while a reversal in course would likely be a catalyst for greater investor frustration," Stanicky adds. The analyst kept an Outperform rating on Allergan with a $220 price target. The stock in midday trading is unchanged at $155.24.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$253.92

-1.7 (-0.67%)

14:27
10/23/19
10/23
14:27
10/23/19
14:27
On The Fly
Fly Intel: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

14:25
10/23/19
10/23
14:25
10/23/19
14:25
Conference/Events
Senate Caucus on International Narcotics Control holds a hearing »

The Caucus holds a…

ALKS

Alkermes

$19.30

0.88 (4.78%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Recommendations
Alkermes analyst commentary  »

Alkermes making some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

TSLA

Tesla

$253.68

-1.94 (-0.76%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Periodicals
Tesla sued over Model S door handle malfunction, CCN says »

The family of a man who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FITB

Fifth Third

$28.11

-0.195 (-0.69%)

14:20
10/23/19
10/23
14:20
10/23/19
14:20
Options
Calls lead puts 8:1 in Fifth Third Bancorp as writer opens position »

Calls lead puts 8:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

IBM

IBM

$134.05

0.02 (0.01%)

, GOOGL

Alphabet Class A

$1,252.30

11.22 (0.90%)

14:18
10/23/19
10/23
14:18
10/23/19
14:18
Periodicals
Google says computer achieves 'quantum supremacy,' Reuters reports »

Alphabet's Google…

IBM

IBM

$134.05

0.02 (0.01%)

GOOGL

Alphabet Class A

$1,252.30

11.22 (0.90%)

GOOG

Alphabet

$1,253.87

11.09 (0.89%)

MSFT

Microsoft

$136.15

-0.24 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 21

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/23/19
10/23
14:17
10/23/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/23/19
10/23
14:16
10/23/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$54.51

0.64 (1.19%)

, WBA

Walgreens Boots Alliance

$54.40

-0.93 (-1.68%)

14:12
10/23/19
10/23
14:12
10/23/19
14:12
On The Fly
Coca-Cola upgrade, Walgreens downgrade among today's top analyst calls »

Check out today's top…

KO

Coca-Cola

$54.51

0.64 (1.19%)

WBA

Walgreens Boots Alliance

$54.40

-0.93 (-1.68%)

SNAP

Snap

$13.23

-0.77 (-5.50%)

BIIB

Biogen

$277.71

-4.25 (-1.51%)

NOW

ServiceNow

$218.44

-9.82 (-4.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

14:09
10/23/19
10/23
14:09
10/23/19
14:09
General news
5-Yr Note Auction Coupon Rate data reported »

5-Yr Note Auction Coupon…

14:09
10/23/19
10/23
14:09
10/23/19
14:09
General news
5-Yr Note Auction Total Amount data reported »

5-Yr Note Auction Total…

SWM

Schweitzer-Mauduit

$39.78

1.11 (2.87%)

14:07
10/23/19
10/23
14:07
10/23/19
14:07
Initiation
Schweitzer-Mauduit initiated  »

Schweitzer-Mauduit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARVN

Arvinas

$19.41

3.01 (18.35%)

14:07
10/23/19
10/23
14:07
10/23/19
14:07
Hot Stocks
Arvinas spikes 17% after platform update including Protac trial data »

Earlier today, Arvinas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

14:04
10/23/19
10/23
14:04
10/23/19
14:04
Periodicals
WeWork plans to cut up to 4,000 jobs in turnaround, FT reports »

WeWork (WE) plans to cut…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CMCSA

Comcast

$45.65

-0.13 (-0.28%)

, CMCSK

Comcast

$0.00

(0.00%)

14:01
10/23/19
10/23
14:01
10/23/19
14:01
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CMCSA

Comcast

$45.65

-0.13 (-0.28%)

CMCSK

Comcast

$0.00

(0.00%)

DHR

Danaher

$137.96

0.76 (0.55%)

MMM

3M

$167.62

0.06 (0.04%)

NOC

Northrop Grumman

$349.80

-2.61 (-0.74%)

RTN

Raytheon

$202.20

-2.69 (-1.31%)

BAX

Baxter

$87.71

0.68 (0.78%)

DOW

Dow Inc.

$47.27

0.45 (0.96%)

HSY

Hershey

$149.87

0.14 (0.09%)

TWTR

Twitter

$38.30

-0.52 (-1.34%)

LUV

Southwest

$53.25

0.355 (0.67%)

TROW

T. Rowe Price

$109.40

1.4 (1.30%)

SWK

Stanley Black & Decker

$153.29

1.98 (1.31%)

HBAN

Huntington Bancshares

$14.48

0.045 (0.31%)

CTXS

Citrix

$103.72

-0.38 (-0.37%)

TSCO

Tractor Supply

$94.34

0.12 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 12

    Dec

HMC

Honda

$26.63

0.015 (0.06%)

14:00
10/23/19
10/23
14:00
10/23/19
14:00
Periodicals
Honda to sell only electric, hybrid cars in Europe starting in 2022, CNN says »

Honda said it intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$225.67

3.75 (1.69%)

, TSLA

Tesla

$255.10

-0.52 (-0.20%)

13:59
10/23/19
10/23
13:59
10/23/19
13:59
Earnings
Notable companies reporting after market close »

Notable companies…

EW

Edwards Lifesciences

$225.67

3.75 (1.69%)

TSLA

Tesla

$255.10

-0.52 (-0.20%)

PYPL

PayPal

$95.99

-1.41 (-1.45%)

MSFT

Microsoft

$136.25

-0.14 (-0.10%)

LVS

Las Vegas Sands

$59.16

0.58 (0.99%)

NOW

ServiceNow

$218.68

-9.58 (-4.20%)

F

Ford

$9.04

-0.025 (-0.28%)

LRCX

Lam Research

$233.15

-1.76 (-0.75%)

EBAY

eBay

$39.03

0.06 (0.15%)

ORLY

O'Reilly Automotive

$400.41

-0.16 (-0.04%)

XLNX

Xilinx

$95.26

-0.75 (-0.78%)

EFX

Equifax

$139.11

-0.15 (-0.11%)

ALGN

Align Technology

$217.63

4 (1.87%)

BMRN

BioMarin

$69.77

2.04 (3.01%)

FBHS

Fortune Brands

$58.73

0.22 (0.38%)

SLM

Sallie Mae

$9.10

0.04 (0.44%)

SAVE

Spirit Airlines

$37.74

0.49 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 07

    Dec

  • 09

    Dec

  • 12

    Dec

HPE

HP Enterprise

$15.93

-0.03 (-0.19%)

13:55
10/23/19
10/23
13:55
10/23/19
13:55
Conference/Events
HP Enterprise to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 09

    Dec

AXON

Axovant Sciences

$0.00

(0.00%)

13:53
10/23/19
10/23
13:53
10/23/19
13:53
Recommendations
Axovant Sciences analyst commentary  »

Axovant Sciences price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGAL

Grupo Financiero

$12.75

0.4 (3.24%)

13:45
10/23/19
10/23
13:45
10/23/19
13:45
Options
Grupo Financiero call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$13.27

-0.73 (-5.21%)

, FB

Facebook

$184.57

2.3 (1.26%)

13:40
10/23/19
10/23
13:40
10/23/19
13:40
On The Fly
#SocialStocks: Snap earnings beat, Facebook CEO testifies about Libra »

Welcome to…

SNAP

Snap

$13.27

-0.73 (-5.21%)

FB

Facebook

$184.57

2.3 (1.26%)

TWTR

Twitter

$38.30

-0.52 (-1.34%)

GOOG

Alphabet

$1,253.59

10.81 (0.87%)

GOOGL

Alphabet Class A

$1,251.72

10.64 (0.86%)

AMZN

Amazon.com

$1,757.06

-9.01 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 21

    Nov

  • 21

    Nov

ALXN

Alexion

$105.87

6.645 (6.70%)

13:37
10/23/19
10/23
13:37
10/23/19
13:37
Recommendations
Alexion analyst commentary  »

Alexion execution…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 04

    Nov

  • 07

    Dec

13:35
10/23/19
10/23
13:35
10/23/19
13:35
General news
Treasury Action: the market took the good auction results in stride »

Treasury Action: the…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
10/23/19
10/23
13:17
10/23/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
10/23/19
10/23
13:16
10/23/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.